Feb. 9, 2023

Ernesto M. Nogueira, CEO at ValueConnected

Ernesto M. Nogueira, CEO at ValueConnected

Ernesto has 27 years of experience leading healthcare strategies to drive access and expansion for new products, developing value propositions for public and private stakeholders, and assessing global market opportunities for healthcare companies. He has worked for both government agencies and global healthcare companies in roles ranging from strategic marketing and new product development to health economics and reimbursement. Also, Ernesto led several Market Access projects across the US, Europe, Latin America, and the Middle East; Ernesto is the CEO and Founder of ValueConnected.

Ernesto also coordinates the ValueConnected team in applying Artificial Intelligence (AI) and Data Science to address significant unmet needs in healthcare, accelerating the adoption rate of medical technologies that can generate value for patients, payers, and providers. He holds an MBA from the University of Texas at Austin, US, and a Bachelor’s degree in Business Administration from Fundação Armando Ávares Penteado(FAAP), in São Paulo, Brazil.

WEBVTT

00:00:00.530 --> 00:00:08.599
Welcome to the Latin MedTech Leaders Podcast, a conversation with MedTech leaders who have succeeded or plan to succeed in Latin America.

00:00:09.029 --> 00:00:12.240
Please subscribe on your favorite podcasting platform.

00:00:12.320 --> 00:00:14.960
Apple Podcast, Spotify, Google Podcast.

00:00:15.269 --> 00:00:29.719
Amazon Music is teacher tuning iHeartRadio, Pandora, or these are Welcome to the Latin MedTech Leaders podcast, a conversation with leaders who have succeeded or plan to succeed in Latin America today.

00:00:29.780 --> 00:00:35.000
Our guest is Ernesto NoDa, c e o, and founder of Value Connected.

00:00:35.289 --> 00:00:50.719
Ernesto has 27 years of experience leading healthcare strategies to dive access and expansion for new products, developing value propositions for both public and private stakeholders, and assessing global market opportunities for healthcare companies.

00:00:50.850 --> 00:00:53.560
So, Ernesto is a pleasure to have you here in the show.

00:00:53.560 --> 00:00:54.000
Welcome.

00:00:54.979 --> 00:00:57.579
Thank you very much, uh, Julio, for inviting me.

00:00:57.581 --> 00:00:58.820
It's a pleasure to be here as well.

00:00:59.840 --> 00:01:00.560
Excellent, Ernesto.

00:01:00.560 --> 00:01:03.320
So let's get started, uh, talking about your journey.

00:01:03.579 --> 00:01:06.680
How is it that you got where you are today,?

00:01:07.480 --> 00:01:07.480
?

00:01:08.030 --> 00:01:30.319
Well, I started selling medical devices in 1997, and I was a rememberable selling what we would consider a techn technological update in that moment in which was, uh, sutures in which the threads were connected to the needles, so the surgeons will not needle surgeon systems will not need to insert the thread into the needle and start suturing.

00:01:30.530 --> 00:01:35.040
So they came connected, and that was a fantastic innovation at that moment.

00:01:35.540 --> 00:01:44.719
And after selling that and other, uh, innovations, which we would call, um, in that period, I started to have some pushbacks from, uh, doctors.

00:01:44.950 --> 00:01:50.400
They were telling me, Ernesto, why is this new technology more expensive?

00:01:50.900 --> 00:01:52.760
Why should we pay for that?

00:01:52.900 --> 00:02:06.519
And then I would describe the features, the technical aspects of the technologies, and basically they would say, yeah, we are convinced, but we are not the ones, uh, signing the check and somebody else, uh, needs to do that.

00:02:06.519 --> 00:02:12.520
And you need to talk to purchasing departments or in certain circumstances, payers, private and public.

00:02:12.819 --> 00:02:25.080
And then when I was started, uh, and I remember to this day, my first, uh, meeting with, uh, purchasing department at a hospital, I was not prepared that you talk to purchasing departments.

00:02:25.080 --> 00:02:30.919
And I did, uh, a strategy that I learned that moment that makes you, you, you look smarter.

00:02:30.990 --> 00:02:46.800
I just took a, a, a notepad and grab it all together with me, and I entered the room of the purchasing department with a notepad than a pen on my hands, because this makes you feel, makes you look more intelligent because intelligence, because intelligence, because I had no idea what to ask.

00:02:47.580 --> 00:03:03.039
And then the purchasing department to the purchasing manager told me, Ernesto, you are the first person from a medical technology company coming to talk to me, and I am the bad guy, and I have to judge products every day, which I don't know what they do.

00:03:03.469 --> 00:03:06.080
I, they, I don't know why they should be used for.

00:03:06.080 --> 00:03:09.319
And the only metric that I have is the price.

00:03:09.699 --> 00:03:19.159
And I mean, if something causes 100 and another causes 50, I am gonna select the 50 because nobody's telling me why the 100 is sufficient.

00:03:19.219 --> 00:03:23.919
And that's the moment that I shift my career to market access.

00:03:24.580 --> 00:03:33.800
And because I, I came from health economics and marketing, I always look as health economics as marketing and reimbursement as sales.

00:03:33.939 --> 00:03:45.719
The only difference is that instead of being marketing sales to physicians, clinical decisionmakers, it's marketing and sales, health, economics, reimbursement to economic decision makers for chasers, payers.

00:03:46.139 --> 00:03:52.449
And then I started moving this career, and of course I could see how intertwined they were.

00:03:52.789 --> 00:04:05.009
And I then I, uh, I wanted to have years, uh, later my MBA in the University of Texas at Austin, United States, working there as well, came back to Latin Americas, I'm from Brazil.

00:04:05.229 --> 00:04:08.169
And then eventually I received an offer to come to Europe.

00:04:08.430 --> 00:04:19.300
And in Europe, because you have such a strong public healthcare system, 95, 90 7% of the healthcare expenditure in Europe, it comes from public payers.

00:04:19.528 --> 00:04:22.980
Then I realized the importance even more of market access.

00:04:22.980 --> 00:04:30.420
And in 2013, I started my own company Value Connected, which now has 38 associates in 36 countries.

00:04:30.439 --> 00:04:32.259
And we have an office in Brazil.

00:04:32.261 --> 00:04:34.220
I'm currently in Sao Paulo right now in Brazil.

00:04:34.439 --> 00:04:42.579
And that's basically doing exactly, uh, what I, uh, perceived as a major challenge in my career.

00:04:42.581 --> 00:04:57.939
So value connected, uh, and the word value and connected, they mean let's connect value to both sales and market access approaches, because the market in general will not be convinced only by technical features.

00:04:57.940 --> 00:05:00.379
And that's basically an overview about my career.

00:05:01.220 --> 00:05:01.220
.

00:05:01.259 --> 00:05:02.060
Fantastic.

00:05:02.660 --> 00:05:04.500
Uh, that's a great story here, Ernesto.

00:05:04.500 --> 00:05:05.019
I loved it.

00:05:05.620 --> 00:05:06.899
Alright, so let's talk about trends.

00:05:06.910 --> 00:05:07.579
Ernesto.

00:05:07.581 --> 00:05:15.980
What do you see happening in the world in Latin America from the economic, political, social standpoint that is relevant to our discussion today?

00:05:15.980 --> 00:05:22.139
How is it that, that what's happening that is making Latin America more attractive, uh, for companies to, to enter the market?

00:05:22.620 --> 00:05:23.180
Right.

00:05:23.370 --> 00:05:30.620
What is interesting to, to mention, I'm gonna focus my, my pointing in Latin America, now we can discuss other markets mm-hmm.

00:05:30.699 --> 00:05:31.060
later.

00:05:31.240 --> 00:05:46.620
But what is very important is that before the Covid pandemic, so that means 2018, 2019, we saw an increasing interest from external companies to enter the Latin American market.

00:05:47.240 --> 00:05:58.360
And in many circumstances, they saw the opportunity for growth, but they were hitting, uh, the ceiling of a reimbursement or hitting the ceiling of market access.

00:05:58.569 --> 00:06:04.399
So there was some discussions already thinking maybe we have already medical societies on our side.

00:06:04.401 --> 00:06:06.920
We have doctors, nurses on our side.

00:06:07.100 --> 00:06:08.600
Why are we not progressing?

00:06:08.600 --> 00:06:16.680
And we saw a lot of interest to understand the dynamics of a payment mechanisms, how, uh, the markets evolve.

00:06:16.680 --> 00:06:20.040
And I can talk more details about certain countries there.

00:06:20.259 --> 00:06:28.000
But then the, the pandemic came and the interest for Latin America did not, uh, change.

00:06:28.338 --> 00:06:31.040
But the healthcare system in Latin America changed.

00:06:31.569 --> 00:06:39.399
We have, um, in Latin America, that's most, uh, um, it's more, uh, is even stronger.

00:06:39.401 --> 00:06:43.720
In Brazil, we have a very significant presence of a private healthcare.

00:06:44.459 --> 00:06:58.120
And what happens is that in private healthcare, the dynamics are a little bit different than in public, because in public, of course, you have a public system that tries to provide the best possible for everyone.

00:06:58.329 --> 00:07:03.519
So if I'm providing an expensive test here, I won't have, uh, money to provide something else there.

00:07:03.521 --> 00:07:11.959
And there is always this, um, discussion for private, if you are paying, um, then means you are covered.

00:07:11.961 --> 00:07:17.319
And basically that population is paying for its, uh, its own healthcare service.

00:07:17.769 --> 00:07:33.360
So in that sense, what we have seen in Latin America is a strong trend towards digitalization, telemedicine, not necessarily going into artificial intelligence, into algorithms that can predict this.

00:07:33.360 --> 00:07:56.279
We don't, we see some interest on that, but a strong interest for remote consultation, um, and telemedicine, and this is happening a lot because the, the, the healthcare systems, especially private, they realized it's much cheaper and more efficient to see or, or, or to diagnose or, or follow up patients like that.

00:07:56.459 --> 00:08:08.800
And even specific systems of the way that the prescriptions are designed, the way that consultations are designed, they are all, um, with QR codes nowadays.

00:08:09.009 --> 00:08:11.519
So there has been an increasing interest on that.

00:08:11.779 --> 00:08:29.160
Now, the other trend that I wanted to, to come, uh, and the last important change, uh, trend, and of course there are others, is the need to take patients out of the hospital because of course the, the hospital capacity is significantly affected by coronavirus.

00:08:29.920 --> 00:08:47.960
We, you have, we have seen in Argentina, Mexico, Colombia, Chile, Brazil, even the academic institutions telling students the, the, the medicine, the school of medicine students to come back home to study from home because they need to use that capacity to treat those patients.

00:08:48.019 --> 00:08:58.399
And of course, thank God, hopefully, um, the demand for, for healthcare to, to coronavirus has been decreasing because of the vaccination, because of many other aspects.

00:08:58.620 --> 00:09:08.220
But in 2020, it was like that, I had many friends who were in medical school and I would call them, and they were at home and they were studying at home.

00:09:08.509 --> 00:09:15.860
So the, the huge capacity was dedicated to, um, ventilation, intubation to treating these patients.

00:09:16.149 --> 00:09:23.820
So a lot of, uh, the demand has to be held up and has to be, uh, uh, managed at, managed at home.

00:09:24.149 --> 00:09:37.620
So a lot of a patient monitoring a lot of, uh, mechanisms to avoid an extensive length of stay due to patient deterioration, infection, they started to become more important in Latin America.

00:09:37.830 --> 00:09:44.860
So in that sense, to summarize, um, that has been a stronger interest, stronger demand for healthcare in Latin America.

00:09:45.080 --> 00:09:49.058
And that demand has not, uh, uh, decreased at all during the pandemic.

00:09:49.230 --> 00:10:00.940
It has changed it to things to keep patients as short as possible in the hospital and or, and or to remove them to the hospital to go to ambulatory or to home care.

00:10:01.759 --> 00:10:02.178
Yes.

00:10:02.179 --> 00:10:02.580
Yes.

00:10:02.980 --> 00:10:10.700
Uh, I, I keep hearing something that says the cell phone or the small phone is a new clinic, right?

00:10:10.720 --> 00:10:11.139
Yes.

00:10:11.140 --> 00:10:13.820
Everything will be done on the cell phone nowadays.

00:10:13.821 --> 00:10:21.058
And I was, uh, patient my cell a couple weeks ago, had an eye infection, and I, for my first time, I had a telemedicine consultation.

00:10:21.090 --> 00:10:24.820
I saw the doctor via video call.

00:10:24.950 --> 00:10:26.620
So it was a, a great experience.

00:10:26.620 --> 00:10:28.539
And he prescribed something to the pharmacy.

00:10:28.541 --> 00:10:30.379
I went to the pharmacy, picked it up, and that was it.

00:10:30.789 --> 00:10:31.820
So simple.

00:10:31.821 --> 00:10:37.940
Didn't have move around the city, search for parking, any of that stuff was a quick thing.

00:10:38.269 --> 00:10:39.539
So absolutely.

00:10:39.541 --> 00:10:43.139
And all these technologies, they had been around for many, many years.

00:10:43.140 --> 00:10:43.460
Yeah.

00:10:43.461 --> 00:10:47.460
And of course, it took Afor, it took an unfortunate case of, uh, uh, COVID.

00:10:48.039 --> 00:10:59.019
But if we look from the positive side, if we make an effort looking from the positive side, the healthcare systems in the world, they developed a lot due to the, uh, pandemic.

00:10:59.020 --> 00:11:05.539
And unfortunately, it's, it's necessary to have this kind of circumstances to get at such a level of development.

00:11:05.919 --> 00:11:06.940
Yes, I agree.

00:11:07.299 --> 00:11:07.379
All right.

00:11:07.380 --> 00:11:10.779
So let's talk about, uh, what you're doing today at Value Connected.

00:11:11.058 --> 00:11:14.340
Uh, can we talk about company, the work that you guys do?

00:11:14.370 --> 00:11:15.980
What's the profile of your clients?

00:11:16.399 --> 00:11:19.178
Are you involved in any exciting projects today?

00:11:19.549 --> 00:11:20.659
So please elaborate

00:11:20.659 --> 00:11:21.058
On that.

00:11:21.059 --> 00:11:21.940
Yes, absolutely.

00:11:22.500 --> 00:11:25.899
Now, we are involving, involved in, in many, many exciting, uh, projects.

00:11:25.900 --> 00:11:31.220
I am passionate about, uh, AI and, um, and digital, uh, healthcare myself.

00:11:31.509 --> 00:11:34.100
So that's something that really gets my attention a lot.

00:11:34.399 --> 00:11:45.299
And, but if looking to what we are doing right now, what the basic, what we do is to accelerate access of patients and providers to the medical technologies they need.

00:11:45.830 --> 00:12:03.480
So what do, the typical problem that we see is that medical companies, uh, launching products in the market, which are products that they truly bring benefits to patients, but the, the medical companies don't know how to translate those benefits to the decision makers.

00:12:03.750 --> 00:12:13.460
What is important to understand, of course, we focus, um, uh, mostly in medical technologies and digital health, but we also work with pharmaceuticals.

00:12:13.558 --> 00:12:20.860
But if you look into digital health and medical technologies, uh, that's the second most innovative industry in the world.

00:12:21.049 --> 00:12:30.620
That means every 35 minutes, that is a new patent for a medic on average, a new patent for a medical technology in, uh, registered.

00:12:31.070 --> 00:12:49.620
So when you, when medical companies come to hospitals, to providers and say, here, dear doctor, dear nurse, dear committee, we have this new exciting product here that does this and that it has a lot of benefits, a lot of research, a lot of efforts, a lot of investments put on that product.

00:12:49.919 --> 00:12:57.220
But the first reaction from the healthcare provider and payer is to think, oh my God, an upfront cost, another cost.

00:12:57.759 --> 00:13:11.259
And especially in Latin America, when we have, uh, a, a more delicate situation in terms of econ economy, especially related to certain markets and certain segments, the breaks are always on.

00:13:11.260 --> 00:13:16.379
There is always some kind of a barrier to say, wait, let's evaluate this technology better.

00:13:16.600 --> 00:13:24.139
And especially in Latin America, if you cannot demonstrate that you save costs, it is going to be very hard.

00:13:24.139 --> 00:13:30.139
You may have very high level evidence, but if you are increasing costs, then it's not impossible.

00:13:30.340 --> 00:13:35.940
With that happens all the time, but it's going to, you need that to make this kind of a argumentation.

00:13:36.149 --> 00:13:45.220
So we help our patients, patients, our clients, to identify how can we translate the benefits of the products to value.

00:13:45.440 --> 00:13:48.500
And value means why should I pay for your product?

00:13:49.120 --> 00:13:54.299
Why is it something that we should use and we should pay for?

00:13:54.480 --> 00:13:58.379
And an example of this was in 2000 and, um, and 18.

00:13:59.139 --> 00:14:04.399
And that's a very special, uh, project to my, uh, to me come to my heart.

00:14:04.400 --> 00:14:09.840
And I will explain why in 2018 we were, were working with, uh, this, uh, this large company.

00:14:09.841 --> 00:14:13.879
Usually we work with large companies, we, but we also work with, uh, startups as well.

00:14:14.100 --> 00:14:26.600
But we were working with this large companies that was trying to obt obtain an inclusion of, um, um, home care mechanical ventilation in the national healthcare system of Brazil.

00:14:27.049 --> 00:14:34.399
So it's a national health system with a 212 million people to include something, the national coverage, it's complicated.

00:14:34.700 --> 00:14:49.600
And we made our analysis, and if we would tell the healthcare system in Brazil to pay for that device, for the, the, for ventilation at home, not only at hospital, but at home, this would increase costs.

00:14:49.700 --> 00:14:58.120
And this kind of obvious, because then you have the ventilators at the hospitals, which are already being used, but then you have to pay for ventilation at home.

00:14:58.700 --> 00:15:02.679
But that, and that's the first reaction when you think about price.

00:15:03.019 --> 00:15:09.240
But then we start our work, which is shifting from price to cost and from cost to value.

00:15:09.250 --> 00:15:13.120
So let's take these two steps from price to cost.

00:15:14.029 --> 00:15:18.759
It's not only about the price of the ventilation, but the cost of the treatment.

00:15:19.269 --> 00:15:28.039
A patient at home is, I would say, represents 25, 30% of the cost of a, of the same patient in the hospital.

00:15:28.330 --> 00:15:33.879
So when you start putting these, uh, costs, they tend to balance them off.

00:15:34.139 --> 00:15:40.559
Not that you mention patients with mechanical ventilation that needed to go to the hospital, they are usually feeling very bad.

00:15:41.009 --> 00:15:43.440
So they did, they require a lot of attention.

00:15:43.450 --> 00:15:52.399
So we made these scenarios to the Brazilian healthcare system, say, listen, this is the cost of the ventilation, but actually let's consider the other courses that are related.

00:15:52.400 --> 00:15:54.679
And we doubt getting into much details.

00:15:54.681 --> 00:15:58.440
We developed eight scenarios to present to the Brazilian government.

00:15:58.570 --> 00:16:02.639
So we, we moved to from price to cost, and then to cost to value.

00:16:02.980 --> 00:16:07.639
The national healthcare system of Brazil has a chronic over demand.

00:16:07.830 --> 00:16:14.759
It's always, um, uh, more, there's a always a line of a patient demanding access to healthcare.

00:16:14.980 --> 00:16:20.759
And these patients, when they don't get treated, most of them will deteriorate.

00:16:21.379 --> 00:16:31.960
And, uh, not that to mention the worst possible scenario, which is, uh, unfortunately the patient, uh, come into death, but there's also the patient getting more expensive to treat.

00:16:32.820 --> 00:16:39.289
So what we showed to the Brazilian government was the value of, uh, uh, treating these patients at home.

00:16:39.870 --> 00:16:49.570
And although it would be slightly more expensive because it would be that capacity in the, in the, in the public hospitals would be released to other patients.

00:16:49.980 --> 00:17:05.210
So we present there and was was a very magical moment for me because, uh, I got to talk to a lot of patients and we got to, to, um, because we need to do this to understand the patient experience.

00:17:05.589 --> 00:17:14.849
And we had the patients that were living in public hospitals for 2, 3, 5 years, they were there because they could not be discharged.

00:17:15.509 --> 00:17:20.690
And by the moment, um, they would have a me mechanical ventilation at home reimbursed.

00:17:20.691 --> 00:17:27.529
They could come back to their families with, uh, in a, in an environment which has a much lower, uh, propensity for infection.

00:17:28.059 --> 00:17:34.210
So, uh, fortunately we, this was a project that they started in 2018 and we succeeded.

00:17:34.309 --> 00:17:40.049
And the Brazilian government eventually, uh, included home care ventilation in the national co um, wow.

00:17:40.730 --> 00:17:40.930
Coverage plan.

00:17:41.519 --> 00:17:42.009
Nice.

00:17:42.680 --> 00:17:43.809
That's super nice.

00:17:43.810 --> 00:17:46.130
And of course, nobody expected that.

00:17:46.190 --> 00:17:51.799
And then coronavirus came and heat and we, uh, we feel very happy.

00:17:51.819 --> 00:18:09.519
And this is one example of the projects that we do, that I, I feel extremely happy and my, my team feel extremely happy that if we could save at least one patient yeah, that could receive mechanical ventilation at home and not at the hospital, especially during coronavirus, then this project was more than than worth it.

00:18:09.690 --> 00:18:11.799
So that's the kind of a projects that we do.

00:18:11.900 --> 00:18:20.180
And again, um, governments, payers, they have so many technologies to look at health policies, so many things.

00:18:20.529 --> 00:18:33.579
It's important to do this work from price to cost, from cost to value, and act more as a partner to these healthcare stakeholders instead of a, a supplier or a manufacturer of a medical products.

00:18:34.339 --> 00:18:34.339
Okay.

00:18:34.940 --> 00:18:34.940
Alright.

00:18:34.990 --> 00:18:46.180
So the question that I have now is about how can a new technology get inserted into the healthcare system in a country, specifically Brazil?

00:18:46.181 --> 00:18:47.858
Let's, is there a framework?

00:18:47.950 --> 00:18:51.940
Is it a step-by-step process, process that ha that a company has to go through?

00:18:51.980 --> 00:18:54.180
Could you please guide us through the process?

00:18:54.181 --> 00:18:58.900
Because I'm sure listeners wanna know how they can get reimbursement for their technologies, right?

00:18:59.410 --> 00:19:00.259
Absolutely.

00:19:00.509 --> 00:19:03.019
We can talk about, uh, other countries as well as well.

00:19:03.020 --> 00:19:05.740
But let's focus on Brazil and I will make some parallels.

00:19:06.140 --> 00:19:08.140
Um, yes to, to Latin America in general.

00:19:08.750 --> 00:19:11.858
So first of all, the first, let's start with good news.

00:19:12.500 --> 00:19:18.299
Uh, Latin America is very, the latinamerican in general is very open to international evidence.

00:19:18.789 --> 00:19:37.700
So for example, if you have a study that was developed in overseas and another country, but it's a a, a study that has a good methodological approach, um, uh, does not need to be fantastic, but it, it has a good description of outcomes, it will be accepted, it will be reviewed.

00:19:38.559 --> 00:19:45.779
Unfortunately, uh, uh, registry data is not so well accepted in Latin America.

00:19:46.579 --> 00:19:57.700
Uh, and we have registry datas with, uh, data databases, excuse me, with thousands of patients, sometimes with dozens of thousands of patients, but they are not so well accepted.

00:19:57.700 --> 00:20:05.660
So have international data, um, uh, especially if it's, uh, randomized and prospective that's extremely well accepted.

00:20:05.750 --> 00:20:06.779
So that's the first thing.

00:20:06.780 --> 00:20:20.380
And of course, case, local case studies talking about Brazil, for all the countries in Latin America, Hulu, Brazil is the country that has the strongest separation between private and public healthcare.

00:20:21.009 --> 00:20:31.950
All other markets in the main markets, Colombia, Mexico, Chile, uh, Argentina, that is a kind of, uh, uh, overlapping and a strong overlapping in Brazil.

00:20:32.150 --> 00:20:39.349
There is a certain overlapping, but there is a strong differentiation the way that medical products are assessed and evaluated.

00:20:39.640 --> 00:20:51.039
So to come into this, um, Brazil, the public healthcare of Brazil has one of the most complete, um, healthcare information databases in the world.

00:20:51.040 --> 00:21:04.480
Really say what is exactly, I know it's, uh, in many circumstances it could be better, but the level of information you cannot obtain in the healthcare system of Brazil data source is second to none.

00:21:05.358 --> 00:21:08.400
Um, uh, I would say even, even to to Germany.

00:21:08.750 --> 00:21:16.079
Having said that, this what how policies are designed, if people are using this information, that's another story.

00:21:16.140 --> 00:21:27.118
But what I'm saying is that in the public healthcare system of Brazil, which covers every whole residents in Brazil, that is a formal process, a formal health technology assessment process.

00:21:27.319 --> 00:21:29.160
Oh, there is a process ready place, okay?

00:21:29.161 --> 00:21:29.640
Mm-hmm.

00:21:29.720 --> 00:21:30.358
exactly.

00:21:30.890 --> 00:21:37.000
So that you can submit your technology and any institutional person in Brazil can submit.

00:21:37.490 --> 00:21:53.200
Of course, if, uh, if a medical society submits a patient association or a doctor will have more influence, a more, a stronger weight, then of course if the company itself submits, but there's no problem for the company self submits.

00:21:53.279 --> 00:21:53.279
Yeah.

00:21:53.599 --> 00:21:53.599
Okay.

00:21:53.601 --> 00:21:58.720
And they evaluate the, the technologies and the cortech is extremely well organized.

00:21:58.721 --> 00:22:02.759
They usually took six months to evaluate a medical technology.

00:22:03.368 --> 00:22:11.279
As soon as the coronavirus, uh, heat, they publish the website, we will continue to review technology, but our timelines are flexible.

00:22:11.608 --> 00:22:16.640
We just, uh, submitted something to, to contact and they responded in six months.

00:22:16.849 --> 00:22:19.759
So, uh, it did not affect very question predictable.

00:22:20.118 --> 00:22:20.118
Yeah.

00:22:20.190 --> 00:22:21.720
Very, very predictable.

00:22:21.858 --> 00:22:31.960
The process itself, and the process is that, and this is specifically now during this, this time because there were other meetings, but everybody's is, uh, uh, hesitant to have face-to-face.

00:22:32.099 --> 00:22:33.240
How does it work?

00:22:33.579 --> 00:22:41.440
You submit your technology or procedure for evaluation in the, for the contech, uh, remember it's not a product.

00:22:41.460 --> 00:22:44.000
You have to submit a procedure procedure.

00:22:44.089 --> 00:22:46.440
So you have a device that can be used in different procedures.

00:22:47.200 --> 00:22:48.559
You'll have to make different applications.

00:22:48.900 --> 00:22:54.079
The Contech will receive that and they will inform if there is something missing like a form or stuff like this.

00:22:54.080 --> 00:23:01.599
Once this is complete, processes starts and they will perform an internal evaluation and they will have an internal meeting.

00:23:01.960 --> 00:23:08.960
And all the meetings for Contech, they are recorded and made available over YouTube, maybe maybe other platforms as well.

00:23:08.961 --> 00:23:15.880
But I always access YouTube and they will discuss and they will come to what is called a preliminary conclusion.

00:23:16.049 --> 00:23:27.200
By the moment they reach a preliminary conclusion, which could be, yes, we think this should be included in the sus, or SUS is the national public healthcare system, or no, we should, uh, not included.

00:23:27.390 --> 00:23:39.279
Then they, uh, made a public, they start of a public consultation that they say, listen, we are open to receive comments from the society, and they are looking specifically for additional evidence.

00:23:39.280 --> 00:23:41.680
The main goal of contact is to assess evidence.

00:23:42.049 --> 00:23:46.079
So they open this public consultation, which usually lasts between 20 and 30 days.

00:23:46.930 --> 00:23:53.589
And after the public consultation, they will call the applicant the person who, or institution who made the application.

00:23:54.089 --> 00:23:58.589
And they will listen to the applicant in a second meeting and they will listen.

00:23:58.990 --> 00:24:02.069
They will, they ask questions by the moment that meeting ends.

00:24:02.070 --> 00:24:11.950
The second that meeting ends, the pplicant leaves, and this is online, pplicant leaves, and the ecotech starts reviewing the public consultations and they reach a final conclusion.

00:24:12.269 --> 00:24:12.269
Okay.

00:24:12.270 --> 00:24:16.470
Which will be published, um, in the, uh, um, in the report.

00:24:16.829 --> 00:24:17.150
The website.

00:24:17.151 --> 00:24:18.349
Yeah, in the website.

00:24:18.500 --> 00:24:21.789
Once this conclusion is made, of course, if it's negative, nothing changes.

00:24:21.960 --> 00:24:33.750
If it is positive, the tech has the road to device, the Ministry of Health of Brazil, but the Contech does not have the road to decide which funds should be used for what.

00:24:34.358 --> 00:24:39.750
So even in our case, when we got mechanical ventilation, we got approval from Contech, but it took six months.

00:24:39.750 --> 00:24:46.910
And that's completely normal from the Ministry of Health to say, okay, we're gonna fund this technology, but let's allocate the money from here from there.

00:24:47.009 --> 00:24:50.390
And that's a complex decision which happens internally.

00:24:50.839 --> 00:25:02.630
So overall from the Applic complete application to a decision for QuTech six months and another six months to have an inclusion in the public healthcare system.

00:25:02.631 --> 00:25:08.509
But that, uh, once again, the applications to Antech can be made at 24 7 anytime you want.

00:25:09.430 --> 00:25:09.430
Okay.

00:25:09.460 --> 00:25:10.589
I'll move into private.

00:25:10.590 --> 00:25:10.990
Now.

00:25:12.460 --> 00:25:21.970
Private healthcare, uh, we have the, a national private agency in Brazil, uh, in Portuguese, it's a n s.

00:25:22.829 --> 00:25:43.690
And what they do is that in private healthcare there is a national list of coverage, but as opposed to public healthcare, the national list of coverage in, in, um, Brazil private does not define a tariff, does not define a payment in the public healthcare in Brazil, that is a national payment, that is a national tariff.

00:25:44.250 --> 00:25:44.490
There's a code.

00:25:44.769 --> 00:25:50.809
There may be some exactly cold, there may be some adjustments based, oh, I am an academic hospital.

00:25:51.170 --> 00:25:53.089
I'm a hospital in a, you know, that needs more funds.

00:25:53.090 --> 00:25:53.690
Absolutely.

00:25:53.691 --> 00:25:56.130
There's a incremental adjustment.

00:25:56.769 --> 00:25:59.170
Minimal for private is completely different.

00:25:59.420 --> 00:26:06.690
So for example, you may uh, add into public coronary artery bypass graft at 10,000.

00:26:07.130 --> 00:26:10.250
Hes in private, it will be coronary artery bypass graft.

00:26:12.680 --> 00:26:18.890
And that's a, and there are two codes in private healthcare, I mean two code systems in private.

00:26:18.891 --> 00:26:24.608
That is the payment for the procedure itself, which will be decided once it is in the mandatory list.

00:26:24.858 --> 00:26:30.490
It will be negotiated between the provider, which could be a hospital, a clinical laboratory.

00:26:30.608 --> 00:26:33.210
It'll be decided between the provider and the payer.

00:26:33.240 --> 00:26:34.450
Each private payer.

00:26:34.829 --> 00:26:38.250
And there is another, uh, payment, which is the physician fee.

00:26:38.990 --> 00:26:42.450
And that there are many physician fees in the same procedure.

00:26:42.451 --> 00:26:48.319
For example, surgical procedure that are physician fees for opening the patient, for the anesthesiologist, for making the procedure.

00:26:48.858 --> 00:27:03.039
All the procedures that are there and these physician fees, they are ranked according to a certain grade, which starts with one A, which is the lowest grade, and then one way, one A, one B, one C to way to b B2C until 14 C.

00:27:03.779 --> 00:27:08.680
And each private payer will say, I will, I pay one a one hundreds.

00:27:08.700 --> 00:27:12.079
The other will say, oh, I pay one a two hundreds.

00:27:12.140 --> 00:27:15.240
And they will decide how much will be there.

00:27:15.240 --> 00:27:24.079
So what is important private, uh, uh, healthcare, uh, that is in comparison to public, that is much less availability of data.

00:27:24.080 --> 00:27:25.440
Data is fragmented.

00:27:25.441 --> 00:27:29.559
There are five types of private plans have private health plans in Brazil.

00:27:30.420 --> 00:27:38.559
And basically they will follow what is in the mandatory list and they will decide, negotiate how much that tariff will be.

00:27:39.019 --> 00:27:45.599
And that's the moment that's this negotiation part that many companies in Brazil don't follow up.

00:27:46.220 --> 00:27:54.480
And it's, uh, out of pocket payments in Brazil happens very frequently, especially in in Sao Paul and Rio, the largest cities.

00:27:54.858 --> 00:28:00.559
But altogether, it represents in the best case scenario, best case scenario, 5% of the market.

00:28:01.358 --> 00:28:02.710
We are talking about this.

00:28:03.089 --> 00:28:11.509
For example, if you take robotic surgery, the, the out-of-pocket payment represents less than 1% of the total demand of the market.

00:28:11.640 --> 00:28:13.630
So in the best case, we're talking about 5%.

00:28:13.631 --> 00:28:19.750
And the problem is that many companies, they turn on their conditioner, they stay relaxed, and they stop there.

00:28:19.750 --> 00:28:21.470
Let's go into our out of pocket.

00:28:21.849 --> 00:28:28.829
And then that is the opportunity to expand that usage applying to the a n s to the national coverage.

00:28:28.950 --> 00:28:31.509
And there are of course in, there's a lot of flexibility.

00:28:31.510 --> 00:28:38.430
There is possibility also, and that's the last point to say, um, potential to make individual agreements with health plans.

00:28:38.569 --> 00:28:43.430
And there are those health plans that own their own providers, their own, their own hospitals and labs.

00:28:43.460 --> 00:28:45.950
Others that are more like insurance companies.

00:28:46.150 --> 00:28:52.549
They are financial institutions that pay for coverage and they will perceive value differently.

00:28:53.269 --> 00:29:02.539
If you come to insurance companies, say we reduce the length of state insurance company will not, will not react the same way as if you tell them we reduce costs.

00:29:03.039 --> 00:29:12.980
But if you come to a, a health plan, which is in Brazil is called group medicine, that has a possibility to have these providers and you say, listen, we will reduce the life of state.

00:29:13.140 --> 00:29:17.819
They will say, wait, wait, you are reducing the cost of my provider that belongs to the same group.

00:29:18.190 --> 00:29:23.940
So it's important, uh, in the making a summary in the public healthcare system, that is one pathway.

00:29:24.819 --> 00:29:32.660
Uh, it's uh, it's a, a very defined pathway, harder to accomplish of course, but of course that's why it's important that we do the proper work.

00:29:32.799 --> 00:29:35.460
But in private, that is a lot of flexibility.

00:29:35.461 --> 00:29:37.619
There's a lot of possibilities that you can take.

00:29:38.579 --> 00:29:38.579
Wow.

00:29:39.500 --> 00:29:47.160
It looks like we can, we can have like five different episodes just to talk about this because we're, we're just starting to, to scratch the surface of Brazil.

00:29:47.161 --> 00:29:49.680
Imagine Mexico, Columbia, Argentina.

00:29:49.990 --> 00:29:51.240
I mean, this is fascinating.

00:29:51.730 --> 00:29:58.440
So, um, we're close to the end of the show and, and, um, I have many more questions, but, uh, we're running out of time.

00:29:58.880 --> 00:30:02.000
, we may, we may do another episode.

00:30:02.000 --> 00:30:04.960
I mean, that's, that's something we can do, uh, uh, certainly.

00:30:05.130 --> 00:30:11.279
So Ernest, Ernesto, the last question I have for you is, what will be your words, your final words of wisdom?

00:30:11.280 --> 00:30:19.799
What would you say to the CEO of a medical technology company from the United States or Europe who is just starting to explore Latin America as a place to do business?

00:30:20.210 --> 00:30:22.680
He wants to start in the region, he wants to serve individual.

00:30:22.789 --> 00:30:27.279
What would be your first tip or two or three tips, uh, to him or her?

00:30:28.029 --> 00:30:28.880
Absolutely.

00:30:28.930 --> 00:30:39.119
So, uh, for somebody wanting to enter in to enter the Latin America market, it could be somebody overseas or could be even a, a local company willing to expand more.

00:30:39.470 --> 00:30:46.359
What is important to understand is that try to involve as early as possible in your strategic planning.

00:30:46.380 --> 00:30:51.279
The perspective of payers don't rely only on key opinion leaders.

00:30:51.470 --> 00:30:52.559
They are not important.

00:30:52.560 --> 00:30:53.519
They are essential.

00:30:53.859 --> 00:30:57.880
You, you won't achieve a success if you don't have opinion leaders in the ground period.

00:30:57.881 --> 00:30:58.599
Absolutely.

00:30:58.601 --> 00:31:01.119
But they are not the only ones taking the decision.

00:31:01.609 --> 00:31:22.359
So it's very expensive to make a huge connection with doctors that why start may start using the product, getting paid out of a pocket and then try to expand from there and then realize you did not have the, the proper evidence upfront and you could have spent the time before collecting that evidence.

00:31:22.690 --> 00:31:39.039
So even if, if you are launching a product in Latin America and you are going to through, go through the regulatory stages, sometimes changing two, three things in your study protocol will make a regulatory study applicable to a reimbursement decision.

00:31:39.150 --> 00:31:44.880
It's not a rocket science to make this, this, this leap, this jump is not even a leap this jump.

00:31:45.339 --> 00:31:56.940
And if you are already, uh, register your product's already registered and so it means you are running against time, then try to involve payers as early as possible and as early as possible means do it now.

00:31:57.069 --> 00:31:59.180
If you have done so, do it now.

00:31:59.181 --> 00:31:59.980
Talk to them.

00:31:59.980 --> 00:32:04.059
Understand what type of evidence are they requesting?

00:32:04.329 --> 00:32:08.539
What do they define as a metric of success?

00:32:08.759 --> 00:32:10.500
How would they evaluate the product?

00:32:10.500 --> 00:32:24.380
Because at the end of the day, and that phrase explains the ravine value is a perception, is not what you as a medical company would think your product has value, but how the decision makers, the local decision makers perceive the product that you're bringing.

00:32:24.381 --> 00:32:26.740
But that's basically the, the final words that I have.

00:32:27.180 --> 00:32:27.259
.

00:32:27.660 --> 00:32:29.059
Alright, Ernesto, thank you so much.

00:32:29.650 --> 00:32:35.460
I, I think, uh, listeners are learning so much from your wisdom and your experience in Latin America.

00:32:36.220 --> 00:32:41.000
And as I said, we should probably plan for another podcast episode, uh, to talk about my pleasure countries.

00:32:41.339 --> 00:32:44.519
But um, thank you so much for being a guest in our show.

00:32:44.710 --> 00:32:49.279
I look forward to being in touch and uh, it was a delightful conversation.

00:32:49.289 --> 00:32:50.200
As you usual

00:32:50.640 --> 00:32:50.640
.

00:32:50.930 --> 00:32:51.519
My pleasure.

00:32:51.520 --> 00:32:52.880
Thank you so much for the opportunity.

00:32:53.069 --> 00:32:54.519
Have a great day everyone.

00:32:54.549 --> 00:32:55.480
Thanks Julia.

00:32:55.880 --> 00:32:56.720
Bye bye-Bye.